Introducing the results of the 2017 (3rd) edition of ‘The Corporate Reputation of Pharma - from the Perspective of Latin-American Patient Groups’. In total, 71 Latin-American patient groups participated in the 2017 survey.
The 13 companies included in the 2017 Latin-American analysis are:
AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer, ngelheim, Eli Lilly, GSK, Janssen, Merck & Co/MSD, Novartis, Pfizer, Roche (Genentech in the US), and Sanofi.
Latin-American patient groups (and the patients they represent), on the whole, take a more positive view of the pharmaceutical industry than patient groups from most other parts of the world. 50% of the Latin-American patient groups respondent to the 2017 survey stated that the industry’s overall corporate reputation was “Excellent” or “Good”. Though slightly down on the equivalent 2016 figure of 52%, the 2017 figure was higher than that from the full 2017 respondent body of 1,330 patient groups worldwide - 43%.
What Latin -American patient groups said
… and patient engagement in R&D
- More medicines for unmet patients’ needs.
- Defining unmet needs by listening to patients.
- Not using the above processes to leverage patient-group support.
Patient-Group Relationships With Pharma, 2017
Industry-Wide Findings, 2017
Rankings Of The 13 Pharma Companies, 2017 V. 2016 Among LATAM Patient Groups Familiar With The Companies
Positionings Of 7 Pharma Companies, 2017 V. 2016 Among US Patient Groups That Work/Partner With The Companies
Profiles Of The 13 Companies, 2017
I. LATAM Patient Groups: Views On Pharma; And Recommendations For Improvement
Ii. Profiles Of Respondent LATAM Patient Groups, 2017
Tables and Charts
The Pharma Industry’S Corporate Reputation, 2015-2017 (According To Latam Patient Groups)
Levels Of Familiarity Of Latam Patient Groups With The 13 Companies, 2017 (And Levels Of
Types Of Relationships That Latam Patient Groups Have With Pharmaceutical Companies, 2017
The Corporate Reputation Of The Pharmaceutical Industry, 2017 V. 2016 - Compared With The Corporate Reputation Of The Pharmaceutical Industry, 2015-2017, According To LATAM Patient Groups
Perceptions Of The Efficacy Of The Pharmaceutical Industry At Various Activities Of Importance To Latam Patient Groups, 2017 [Chart And Table]
Perceptions Of The Efficacy Of The Pharmaceutical Industry At Various Activities (According To Latam Patient Groups, 2017 V. 2016 V. Patient Groups Worldwide 2017)
Latam Patient Groups’ Views On The Various Activities Of Pharma, Compared With The Views Of Patient Groups From 17 Other Regions/Countries, Plus The Views Of Patient Groups Worldwide - All 2017
Rankings Of Individual Pharma Companies, 2017 V. 2016 (According To LATAM Patient Groups Familiar With The Company)
Positionings Of Individual Pharma Companies, 2017 V. 2016 (According To LATAM Patient Groups That Work/Partner With The Company)
Profiles Of The 13 Companies, 2017
CHARTS AND TABLES FOR EACH OF THE 13 COMPANIES:
Number of LATAM patient groups claiming familiarity with the company, 2017.
Number of LATAM patient groups saying that they had a working relationship with the company, 2017.
Company scores among LatAm patient groups familiar with the company, and which worked with the company, for each of the 12 indicators of corporate reputation, 2017.
Percentage of the LATAM patient groups that worked with the company, but which also worked with other companies, 2017.
Profile of respondent LATAM patient groups familiar, and working, with the company, 2017: countries; specialties; geographic remit; and types of relationships.
The company’s PCRIs (Patient Corporate Reputation Index) for each of the 12 indicators - as assessed by LATAM patient groups, 2017 v. 2016 v. 2015.
Overall rankings for the company, according to LATAM patient groups familiar with the company, 2017.
Overall positionings for the company, according to LATAM patient groups that work with the company, 2017.
Company rankings for each of the 12 indicators, according to LATAM patient groups familiar, or working, with the company, 2017 v. 2016.
The company’s Net Promoter Score, 2017, as assessed by LATAM patient groups working with the company.